Plasma sphingolipid changes with autopsy‐confirmed Lewy body or Alzheimer's pathology
Open Access
- 1 January 2016
- journal article
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 3 (1) , 43-50
Abstract
Introduction: The clinical and pathological phenotypes of Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) often overlap. We examined whether plasma lipids differed among individuals with autopsy‐confirmed Lewy Body pathology or AD pathology.Methods: We identified four groups with available plasma 2 years before death: high (n = 12) and intermediate‐likelihood DLB (n = 14) based on the third report of the DLB consortium; dementia with Alzheimer's pathology (AD; n = 18); and cognitively normal with normal aging pathology (n = 21). Lipids were measured using ESI/MS/MS.Results: There were overall group differences in plasma ceramides C16:0, C18:1, C20:0, and C24:1 and monohexosylceramides C18:1 and C24:1. These lipids did not differ between the high‐likelihood DLB and AD groups, but both groups had higher levels than normals. Plasma fatty acid levels did not differ by group.Discussion: Plasma ceramides and monohexosylceramides are elevated in people with dementia with either high‐likelihood DLB or AD pathology.Keywords
Funding Information
- NIH/NIA (U01 AG 37526, P50 AG016574)
- Alzheimer Drug Discovery Foundation
- Lewy Body Dementia Association
This publication has 28 references indexed in Scilit:
- Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot StudyPLOS ONE, 2013
- Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in SynucleinopathiesCell, 2011
- Serum sphingomyelins and ceramides are early predictors of memory impairmentNeurobiology of Aging, 2010
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's DiseaseNew England Journal of Medicine, 2009
- Association of Glucocerebrosidase Mutations With Dementia With Lewy BodiesArchives of Neurology, 2009
- Validation of the Neuropathologic Criteria of the Third Consortium for Dementia With Lewy Bodies for Prospectively Diagnosed CasesJournal of Neuropathology & Experimental Neurology, 2008
- Lipids as Modulators of Proteolytic Activity of BACEJournal of Biological Chemistry, 2005
- Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase–ceramide pathwayJournal of Cell Biology, 2004
- Ceramide Stabilizes β-Site Amyloid Precursor Protein-cleaving Enzyme 1 and Promotes Amyloid β-Peptide BiogenesisJournal of Biological Chemistry, 2003
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991